First-week expansion of activated peripheral B-cell subsets is associated with grade 3 or higher immune-related adverse events after nivolumab plus ipilimumab
- 1Kobe University Hospital and Graduate School of Medicine
Abstract
BackgroundAlthough immune checkpoint inhibitors (ICIs) cause grade 3 or higher immune-related adverse events (irAEs), validated biomarkers for identifying patients at risk of these events are lacking. Given the potential contribution of B-cells to irAE development, we evaluated whether early changes in circulating B-cell subsets after nivolumab plus ipilimumab were associated with subsequent severe irAEs.
Materials and MethodsThis prospective observational study included 12 patients who received nivolumab plus ipilimumab, and an exploratory cohort of five patients who received anti-PD-1 monotherapy. Blood was sampled before treatment, at week 1, and before cycle 2. Flow cytometry quantified CD21low B-cells, CD27+IgD- class-switched B-cells, plasmablasts, and CD19+CD138+ plasma cells. irAEs were assessed for 6 months, and fold changes at week 1 were compared between patients with and without severe irAEs. Paired immunoglobulin G B-cell receptor (BCR) repertoires were analyzed in four patients with grade 3 or higher irAEs. One patient developed myasthenia gravis, and anti-acetylcholine receptor (AChR) antibody was measured in serial serum samples.
ResultsIn the nivolumab plus ipilimumab patients, grade 3 or higher irAEs occurred in five patients. Week-1 increases in all four activated B-cell subsets were significantly greater in these patients, whereas total CD19+ B-cell changes did not differ. Rarefied IgG BCR diversity generally increased in repertoires derived from peripheral blood mononuclear cells, while Gini coefficients decreased in all paired repertoires. In the myasthenia gravis case, anti-AChR antibody exceeded the reference range by Day 11, before symptoms and diagnosis.
ConclusionFirst-week expansion of activated peripheral B-cell subsets after nivolumab plus ipilimumab was associated with subsequent severe irAEs. These findings support future studies of early B-cell monitoring within integrated multimarker assessments of irAE risk.
Related
- Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer
- 484 Phase II neoadjuvant study of nivolumab alone and in combination with relatlimab or ipilimumab in resectable head and neck cancer
- Peritoneal mesothelioma showing a remarkable response to nivolumab plus ipilimumab in a patient with Lynch syndrome: A case report and literature review
- Marked Response to Nivolumab Plus Ipilimumab After the Failure of Two Prior Immune Checkpoint Inhibitor–Based Regimens Including CTLA-4 Blockade in Advanced Hepatocellular Carcinoma
- Neoadjuvant pepinemab in combination with nivolumab and/or ipilimumab in resectable metastatic melanoma: a pilot biomarker-driven trial
BibTeX
@misc{takakura2026firstweek,
title = {{First-week expansion of activated peripheral B-cell subsets is associated with grade 3 or higher immune-related adverse events after nivolumab plus ipilimumab}},
author = {h. takakura and Y. Funakoshi and T. Koyama and T. Sasaki and E. Fukuda and J. M. Lee and K. Kurata and Y. Inui and K. Yakushijin and S. Kimbara and Y. Nagatani and N. Kiyota and H. Minami},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.09.26362435},
url = {https://www.medrxiv.org/content/10.64898/2026.09.09.26362435v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - First-week expansion of activated peripheral B-cell subsets is associated with grade 3 or higher immune-related adverse events after nivolumab plus ipilimumab
AU - h. takakura
AU - Y. Funakoshi
AU - T. Koyama
AU - T. Sasaki
AU - E. Fukuda
AU - J. M. Lee
AU - K. Kurata
AU - Y. Inui
AU - K. Yakushijin
AU - S. Kimbara
AU - Y. Nagatani
AU - N. Kiyota
AU - H. Minami
PY - 2026
DA - 2026/09/09
PB - medRxiv
DO - 10.64898/2026.09.09.26362435
UR - https://www.medrxiv.org/content/10.64898/2026.09.09.26362435v1
AB - BackgroundAlthough immune checkpoint inhibitors (ICIs) cause grade 3 or higher immune-related adverse events (irAEs), validated biomarkers for identifying patients at risk of these events are lacking. Given the potential contribution of B-cells to irAE development, we evaluated whether early changes in circulating B-cell subsets after nivolumab plus ipilimumab were associated with subsequent severe irAEs. Materials and MethodsThis prospective observational study included 12 patients who received nivolumab plus ipilimumab, and an exploratory cohort of five patients who received anti-PD-1 monotherapy. Blood was sampled before treatment, at week 1, and before cycle 2. Flow cytometry quantified CD21low B-cells, CD27+IgD- class-switched B-cells, plasmablasts, and CD19+CD138+ plasma cells. irAEs were assessed for 6 months, and fold changes at week 1 were compared between patients with and without severe irAEs. Paired immunoglobulin G B-cell receptor (BCR) repertoires were analyzed in four patients with grade 3 or higher irAEs. One patient developed myasthenia gravis, and anti-acetylcholine receptor (AChR) antibody was measured in serial serum samples. ResultsIn the nivolumab plus ipilimumab patients, grade 3 or higher irAEs occurred in five patients. Week-1 increases in all four activated B-cell subsets were significantly greater in these patients, whereas total CD19+ B-cell changes did not differ. Rarefied IgG BCR diversity generally increased in repertoires derived from peripheral blood mononuclear cells, while Gini coefficients decreased in all paired repertoires. In the myasthenia gravis case, anti-AChR antibody exceeded the reference range by Day 11, before symptoms and diagnosis. ConclusionFirst-week expansion of activated peripheral B-cell subsets after nivolumab plus ipilimumab was associated with subsequent severe irAEs. These findings support future studies of early B-cell monitoring within integrated multimarker assessments of irAE risk.
ER -